Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
11,534 total articles
Fossil Group, Inc. reported net sales of $225 million for Q1 2026, a slight decrease due to shorter fiscal period and lower direct-to-consumer sales. Despite a 3.6% reported sales drop, the company achieved operating income of $12 million versus a loss last year, reflecting restructuring benefits and cost reductions. Gross margin declined slightly …
Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) reported its Q1 2026 financial results along with updates on the commercialization progress of GraftAssureDx, its kidney transplant monitoring assay. The company is advancing toward FDA marketing authorization expected later in 2026, with encouraging FDA dialogues. International research data valida…
Teekay Corporation Ltd. released its first quarter 2026 update and announced a special cash dividend of $1.00 per common share payable on June 2, 2026. The company operates in international crude oil marine transportation and related marine services with a fleet of mid-sized tankers and provides ship-to-ship transfer services.
Fluent, Inc. reported Q1 2026 financial results highlighting a strong performance in its Commerce Media Solutions segment, which grew 104% year-over-year to $25.9 million and now represents 58% of total revenue. Despite a 19% decline in total revenue due to divestiture of Call Solutions, Fluent expects full-year double-digit revenue growth driven b…
Eledon Pharmaceuticals announced first quarter 2026 financial results and recent business highlights, including significant clinical milestones for their lead drug candidate tegoprubart. Key achievements include 100% insulin independence in type 1 diabetes patients post-islet transplantation, FDA Orphan Drug designation for liver transplantation, a…
Teekay Tankers Ltd. announced its financial results for the first quarter ended March 31, 2026, and declared a fixed quarterly cash dividend of $0.25 per share alongside a special cash dividend of $1.00 per share, payable June 2, 2026. The company operates a fleet of 33 double-hull tankers and provides marine services, including ship-to-ship transf…
Brilliant Earth Group, Inc., a leader in ethically sourced fine jewelry, announced its participation in the B. Riley Securities Annual Investor Conference and the TD Cowen 10th Annual Future of the Consumer Conference. The company will engage with investors through meetings and a fireside chat webcast. With a mission focused on transparency and sus…
U.S. Global Investors reported net income of $2.7 million (EPS $0.23) for Q3 fiscal 2026, reversing prior losses. Operating revenues increased 10% sequentially and 31% year-over-year, driven by gains in gold and natural resources funds. Average assets under management reached $1.6 billion, the highest since mid-2024, bolstered by strong performance…
Snail, Inc., a Nasdaq-listed independent game developer and publisher, reported for Q1 2026 a 35.7% increase in net revenues to $27.3 million, a return to net income positive of $2.1 million, and strong operational performance with rising unit sales and daily active users of ARK franchise titles. The company outlined an extensive content pipeline i…
Robinhood Markets, Inc. reported robust operating data for April 2026, with funded customers reaching 27.6 million, total platform assets increasing 12% from March to $345 billion, and strong year-over-year growth in equities and options trading volumes. Despite a decline in crypto trading volumes from the prior month, overall trading activity and …
Seer, Inc. announced its first quarter 2026 financial results, reporting revenue of $2.8 million, down 34% year-over-year due to a depressed academic funding environment and increased competition. Despite the revenue drop, the company achieved key milestones including doubling independent publications, securing a major collaboration in Singapore, s…
Spero Therapeutics announced its financial results for Q1 2026 and provided a business update highlighting progress on its NDA for tebipenem HBr, an oral carbapenem antibiotic for complicated urinary tract infections, with an FDA PDUFA decision expected on June 18, 2026. The company reported a reduced net loss compared to last year, maintains a str…
Longeveron Inc. reported its Q1 2026 financial results highlighting ongoing development of laromestrocel, a proprietary stem cell therapy for serious conditions including Hypoplastic Left Heart Syndrome (HLHS) and Alzheimer's disease. The company raised $15 million in a private placement to fund current operations and expects topline data from a pi…
Oruka Therapeutics announced robust Phase 1 and Phase 2 trial data for its novel biologics ORKA-001 and ORKA-002 targeting chronic skin diseases, particularly plaque psoriasis. ORKA-001 demonstrated high rates of complete skin clearance with a potential for annual dosing. The company raised $700 million in a public offering, extending its cash runw…
PDF Solutions, Inc., a provider of data solutions for the semiconductor and electronics industry, announced an underwritten public offering of 3,806,924 shares of its common stock, including shares sold by a selling stockholder and the company itself. The offering includes an underwriter option to purchase additional shares and is subject to market…
Allogene Therapeutics reported encouraging interim results from its Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel) in first-line Large B-cell Lymphoma (LBCL). The analysis showed significantly higher minimal residual disease (MRD) clearance in the cema-cel arm versus observation (58.3% vs 16.7%) with no treatment-related ser…
vTv Therapeutics reported Q1 2026 financials showing a $24.1 million net income driven by a $20 million upfront payment from a license agreement amendment with Newsoara Biopharma. The company is on track to complete enrollment in its Phase 3 CATT1 trial for cadisegliatin, a novel oral adjunctive therapy for type 1 diabetes, by Q3 2026, and believes…
Equillium reported Q1 2026 results showcasing progress on its investigational drug EQ504, an aryl hydrocarbon receptor modulator targeting inflammatory diseases. The company plans a Phase 1 study initiation in mid-2026 with data expected about six months later. A strategic leadership appointment and a recent $35 million financing bolster developmen…
Usio, Inc. announced its first quarter 2026 financial results, highlighting a 16% revenue increase to $25.5 million, surpassing consensus estimates by 9%. The company achieved record quarterly revenue, processing volume, and transactions, with total payment dollars processed rising 28% year-over-year. Adjusted EBITDA rose 12% to $0.8 million, and n…
Journey Medical Corporation announced its Q1 2026 financial results showing a 21% year-over-year increase in total revenues to $16.0 million driven by Emrosi® sales reaching $6.3 million. The company reported a narrower net loss of $2.2 million compared to $4.1 million in the prior year quarter and positive adjusted EBITDA of $0.6 million. Cash res…
aTyr Pharma, a clinical stage biotechnology company focused on developing novel therapies derived from its proprietary tRNA synthetase platform, will participate in two investor conferences in New York in May and June 2026. The company will hold investor meetings and a fireside chat featuring CEO Sanjay S. Shukla, with webcasts and replays availabl…
Capital Southwest Corporation reported financial results for the fourth quarter and fiscal year ended March 31, 2026. The company achieved a 17% growth in total investment portfolio to $2.1 billion and a 13.5% increase in investment income over the prior year. Despite a slight decrease in NAV per share to $16.69, Capital Southwest maintained stable…
Grocery Outlet Holding Corp. announced first quarter fiscal 2026 financial results showing a 3.6% increase in net sales to $1.17 billion driven by new store openings. However, comparable store sales declined by 1.0% and the company recorded a net loss of $180.3 million largely due to a $158 million non-cash goodwill impairment and restructuring cha…
MacroGenics reported strong Q1 2026 financial results highlighted by strategic divestiture of manufacturing operations to Bora Pharmaceuticals and expanded monetization of ZYNYZ royalties, expected to generate up to $202.5 million in proceeds. The company is focusing on its core antibody-based oncology pipeline with multiple upcoming data readouts …
Aquestive Therapeutics reported strong first quarter 2026 results with a 66% revenue increase driven by license, royalty, and manufacturing sales. The company reaffirmed plans to resubmit the NDA for Anaphylm, a non-invasive epinephrine sublingual film, to the FDA in Q3 2026 following successful alignment on study designs. Positive clinical data fo…
